Cargando…

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)

BACKGROUND: Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by the deficiency of iduronate-2-sulfatase (IDS). In affected patients, glycosaminoglycan (GAG) accumulates in the lysosomes of many organs and tissues contributing to the pathology as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Young Bae, Cho, Sung Yoon, Park, Sung Won, Kim, Su Jin, Ko, Ah-Ra, Kwon, Eun-Kyung, Han, Sun Ju, Jin, Dong-Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614543/ https://www.ncbi.nlm.nih.gov/pubmed/23497636 http://dx.doi.org/10.1186/1750-1172-8-42

Ejemplares similares

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
por: Cho, Sung Yoon, et al.
Publicado: (2014)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II
por: Cho, Sung Yoon, et al.
Publicado: (2015)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
por: Yamanishi, Ryutaro, et al.
Publicado: (2019)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Perioperative airway management for aortic valve replacement in an adult with mucopolysaccharidosis type II (Hunter syndrome)
por: Suzuki, Kazuchika, et al.
Publicado: (2018)

Carpal Tunnel Syndrome in the Setting of Mucopolysaccharidosis II (Hunter Syndrome)
por: Argenta, Anne E., et al.
Publicado: (2017)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome—Type II Mucopolysaccharidosis
por: Kim, Hantai, et al.
Publicado: (2021)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy
por: Giugliani, Roberto, et al.
Publicado: (2014)

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
por: Kim, Katherine H., et al.
Publicado: (2014)

A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients
por: Lee, Ok Jeong, et al.
Publicado: (2012)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
por: Raluy-Callado, Mireia, et al.
Publicado: (2013)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
por: Tomita, Kazuyoshi, et al.
Publicado: (2021)

Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II)
por: Lin, Hsiang-Yu, et al.
Publicado: (2019)

Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): a case report
por: Shah, Gauri Shankar, et al.
Publicado: (2010)

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
por: Chiong, Mary Anne D., et al.
Publicado: (2017)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
por: Racoma, Marie Julianne C., et al.
Publicado: (2021)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
por: Chan, Mei-Yan, et al.
Publicado: (2023)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
por: Yee, Karen S., et al.
Publicado: (2023)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl
por: Semyachkina, A. N., et al.
Publicado: (2019)

Challenges in the Management of Mucopolysaccharidosis Type II (Hunter's Syndrome) in a Developing Country: a Case Report
por: Rasheeedah, Ibraheem, et al.
Publicado: (2015)

Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
por: Amartino, H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_skd1hgpurst0lj62dbgkh48pm4